» Articles » PMID: 35488064

Genetic Genealogy Uncovers a Founder Deletion Mutation in the Cerebral Cavernous Malformations 2 Gene

Overview
Journal Hum Genet
Specialty Genetics
Date 2022 Apr 29
PMID 35488064
Authors
Affiliations
Soon will be listed here.
Abstract

Cerebral cavernous malformations (CCM) are vascular malformations consisting of collections of enlarged capillaries occurring in the brain or spinal cord. These vascular malformations can occur sporadically or susceptibility to develop these can be inherited as an autosomal dominant trait due to mutation in one of three genes. Over a decade ago, we described a 77.6 Kb germline deletion spanning exons 2-10 in the CCM2 gene found in multiple affected individuals from seemingly unrelated families. Segregation analysis using linked, microsatellite markers indicated that this deletion may have arisen at least twice independently. In the ensuing decades, many more CCM patients have been identified with this deletion. In this present study we examined 27 reportedly unrelated affected individuals with this deletion. To investigate the origin of the deletion at base pair level resolution, we sequenced approximately 10 Kb upstream and downstream from the recombination junction on the deleted allele. All patients showed the identical SNP haplotype across this combined 20 Kb interval. In parallel, genealogical records have traced 11 of these individuals to five separate pedigrees dating as far back as the 1600-1700s. These haplotype and genealogical data suggest that these families and the remaining "unrelated" samples converge on a common ancestor due to a founder mutation occurring centuries ago on the North American continent. We also note that another gene, NACAD, is included in this deletion. Although patient self-reporting does not indicate an apparent phenotypic consequence for heterozygous deletion of NACAD, further investigation is warranted for these patients.

Citing Articles

Unveiling the role of TGF-β signaling pathway in breast cancer prognosis and immunotherapy.

Zheng Y, Li L, Cai W, Li L, Zhang R, Huang W Front Oncol. 2024; 14:1488137.

PMID: 39664194 PMC: 11631921. DOI: 10.3389/fonc.2024.1488137.

References
1.
Horne M, Flemming K, Su I, Stapf C, Jeon J, Li D . Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. Lancet Neurol. 2015; 15(2):166-173. PMC: 4710581. DOI: 10.1016/S1474-4422(15)00303-8. View

2.
Reddy R, Efimenko I, Chertman W, Kohn T, Diaz P, Seetharam D . Whole Exome Sequencing Identifies a Rare Mutation in NACAD as a Possible Cause of COVID Orchitis in Brothers. Urology. 2021; 159:83-86. PMC: 8526121. DOI: 10.1016/j.urology.2021.09.021. View

3.
Booth K, Azaiez H, Smith R . () c.991-15_991-13delTTC: Founder Mutation or Mutational Hotspot?. Int J Mol Sci. 2020; 21(11). PMC: 7312536. DOI: 10.3390/ijms21113951. View

4.
Laberge-Le Couteulx S, Jung H, Labauge P, Houtteville J, Lescoat C, Cecillon M . Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet. 1999; 23(2):189-93. DOI: 10.1038/13815. View

5.
Kichaev G, Bhatia G, Loh P, Gazal S, Burch K, Freund M . Leveraging Polygenic Functional Enrichment to Improve GWAS Power. Am J Hum Genet. 2019; 104(1):65-75. PMC: 6323418. DOI: 10.1016/j.ajhg.2018.11.008. View